Skip to main content
. 2021 May 28;16(5):e0252621. doi: 10.1371/journal.pone.0252621

Table 3. Result comparison between 107 serum samples tested by the Luminex xMAP and Roche anti-NC ECLIA anti-SARS-CoV-2 serologic assays.

Roche anti-NC ECLIA (Serum) PPA (95% CI) NPA (95% CI) OC (95% CI) Kappa (95% CI)
Positive Negative 90% (57.4–99.9%) 99% (93.8–99.9%) 98.1% (93–99.9%) 0.89 (0.74–1.0)
Luminex xMAP (serum) Positive 9 1
Negative 1 96